Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

ImmunityBio Q3 EPS $(0.07) Beats $(0.10) Estimate, Sales $32.061M Beat $31.880M Estimate

Author: Benzinga Newsdesk | November 05, 2025 01:48am
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 31.37 percent. This is a 50 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $32.061 million which beat the analyst consensus estimate of $31.880 million by 0.57 percent. This is a 425.07 percent increase over sales of $6.106 million the same period last year.

Posted In: IBRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist